Drug Profile
MMV 390048
Alternative Names: MMV 048; MMV-390048Latest Information Update: 01 Oct 2021
Price :
$50
*
At a glance
- Originator Griffith University; University of Cape Town
- Developer Medicines for Malaria Venture; Technology Innovation Agency; University of Cape Town
- Class Amines; Aminopyridines; Antimalarials; Fluorinated hydrocarbons; Pyridines; Small molecules; Sulfones
- Mechanism of Action 1-phosphatidylinositol 4-kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Malaria
Most Recent Events
- 01 Oct 2021 Chemical structure information added
- 21 Apr 2018 Efficacy, adverse events and pharmacokinetic data from two phase Ib trials in Malaria presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
- 02 Feb 2018 Medicines for Malaria Venture withdraws a phase I trial for Malaria (Prevention) in Germany prior to enrolment, for repositioning of target indication (PO) (NCT03195387)